Another study performed by Vogt et al. evaluated the efficacy of combination of two mature-DC vaccines, which were transfected with adenoviral vector DNA containing a gene encoding either the HCC tumor marker AFP or the immune co-stimulatory molecule CD40 ligand (CD40L), in treating HCC [56]. The gene discussed is AFP; the disease is neoplasm.